Many publishers have made their coronavirus-related publications free to read online, including ours, Future Science Group. Here’s a brief overview of what’s available.
We are currently fast-tracking submissions on this vital topic, so please get in touch if you would like to discuss a potential submission.
This study explored biomarkers for disease progression and outcome.
This study describes an optimized diagnostic policy for patients with respiratory tract infections, developed at an emergency department in The Netherlands.
This case report describes a suspected COVID-19 case that had a history of close contact with a COVID-19 patient. The diagnosis was confirmed after the SARS-CoV-2 nucleic acid was detected after four sputum sample tests.
Gold nanoparticles and semiconductor quantum dots in colorimetric and immunochromatographic assays, silica nanoparticles in the polymerase chain reaction and spike protein nanospheres as antigen carriers and adjuvants in vaccine formulations present notable examples in diagnostics and prevention. However, uses of nanoparticles in coronavirus infection treatments have been merely sporadic. This perspective article discusses.
This report describes a novel hypothetical approach combining available broad-spectrum antiviral agents such as nucleoside analogs with potential inhibitors of NendoU, for example nsp15 RNA substrate mimetics.
Here, the authors applied a molecular docking method to study the binding stability of remdesivir, ritonavir and chloroquine with SARS-CoV-2 Mpro.
This review provides rationale for the repurposing of a dual plasmid, currently in Phase III cancer trials, against SARS-CoV-2.
This article provides a snapshot of requirements for SARS-CoV-2 assays, and suggests ways their development and implementation could be accelerated effectively.
This study provides evidence that some medicinal compounds exert antiviral activity against the SARS-COV-2 virus and could be further exploited for the treatment of this disease.
This report recommends a number of strategies related to our exposome that could help ameliorate the effects of infection with SARS-CoV-2.
This literature review examined the therapy options for SARS and MERS and discussed their potential against SARS-CoV-2.
This article discusses the potential utility of the BCG vaccine for COVID-19, and ongoing trials.
This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2, including the use of research previously done for SARS-CoV.
This study sought to predict and analyze the structure and function of SARS-CoV-2 proteins.
ARDS can occur with COVID-19. This review examines preclinical and clinical trials examining the utility of mesenchymal stem cells in combating the inflammatory reactions that cause it.
This piece examined Gamunex-C and Flebogamma DIF for activity against SARS-CoV-2 antigens.
Could COVID-19 research end the debate around randomized clinical trials vs real world evidence (RWE)? This Commentary piece investigates RWE in COVID-19 and looks to the future.
This article reports on recent studies looking at harnessing nanoparticles for diagnostics or antivirals. It also looks to the use of nanomaterials as vaccines and nanosensors.
There is urgent need to understand the phylogeny, divergence and origin of SARS-CoV-2. With a recent study claiming that there was 17% divergence between SARS-CoV-2 and RaTG13 (a SARS-related coronaviruses) on synonymous sites by using sequence alignment, this study re-analyzed the sequences of the two coronaviruses with the same methodology. The authors demonstrate that the divergence between SARS-CoV-2 and RaTG13 has been overestimated.
As the novel coronavirus SARS-CoV-2 spreads around the world, scientists have raced to develop vaccines and tests in order to curb the infection. This article investigates their efforts thus far.
This report discusses the validity of applying classic evolutionary theories and formula to the evolution of RNA viruses, raising several confounding factors that could jeopardize validity.
This piece reviews the challenges in the use of extracorporeal membrane oxygenation (ECMO) as a mechanical support option for critical COVID-19 patients.
This Commentary piece discusses whether exhaled breath condensates should be tested as a noninvasive sampling method in the clinic, and what technologies might be useful to help speed up sampling and screening during pandemics.
With the pandemic affecting most laboratories, this article discusses measures that might be taken to reduce the chance of COVID-19 spread, and its impact on laboratory analysts.
This Commentary addresses the challenges associated with the use of miRNAs as biomarkers and therapeutic targets for respiratory diseases, and the advantages of nonviral methods of delivery.
High-frequency longitudinal tracking of inflammation using dried blood microsamples provides a new window for personalized monitoring of infections, chronic inflammatory disease and clinical trials of anti-inflammatory drugs. This research article sheds new light on the dynamic regulation of acute phase responses, offering a new approach to visualization of multidimensional inflammation trajectories.
Efforts to repurpose drugs are underway in a bid to tackle the COVID-19 pandemic. This Editorial discusses whether carefully combined cocktails could be more effective than individual use, and how to determine that combination.
COVID-19 and co-morbidities
This Commentary discuss issues specific to the use of immune checkpoint inhibitors by patients with triple-negative breast cancer during the current pandemic.
This review examined available data regarding the effects exerted by both SARS-CoV-2 and the most widespread immunotherapy treatments in order to hypothesize mechanisms underlying potential and mutual interaction.
This article discusses the potential short- and long-term effects of the pandemic on cancer research.
This article seeks to establish an association between novel coronavirus sequelae and cancer through a literature review on COVID-19 mechanisms of action, molecular responses it elicits upon infection and tumorigenesis pathways.
This Editorial discusses the challenges and constraints facing HSCT during the current pandemic.
This editorial discusses cases where infected cancer patients showed negative, and provides some recommendations for management.
This survey sought to assess which and when measures to reduce coronavirus disease (COVID-19) spread were applied in 12 medical oncology departments, and provides recommendations.
In this Editorial the authors discuss whether cardiovascular disease could be considered as a biomarker for an increased risk of COVID-19 infection and related poor prognosis.
This paper aims to address the current status of the COVID-19 in patients with cancer overall and suggests an optimal approach to patients with metastatic prostate cancer.
Treatment for prostate cancer has been affected by the current pandemic, with no accepted guidelines for management. This article discusses and provides some recommendations.
This research article describes the course and outcome for 25 cancer patients treated in one Italian general hospital.
This Editorial discusses the impacts the COVID-19 impact has had on cancer clinical trials.
This Editorial discusses whether telemedicine is a threat to the effective oncology patient care during the current pandemic, or whether it could in fact revolutionize clinical practice.
This article comments on the various challenges facing the management of lung cancer care during the COVID-19 pandemic – including diagnosis, surgery, therapies, supportive care and screening. It also touches on effects on smoking cessation and patient lifestyle.
Several million people around the globe are affected by chronic respiratory disorders, which could also be exacerbated by COVID-19. This article discusses the need to investigate the pathology surround these diseases further, and specifically the concept of airway remodeling for drug delivery.
Cardiovascular risk factors are strongly influenced by quarantine. This article discusses how, and the potential impacts.
With the symptoms of COVID-19 posing significant challenges for lung cancer patients, this articles re-evaluates the risks, benefits and delivery of immunotherapy for non-small-cell lung cancer during the COVID-19 pandemic.
This Editorial seeks to provide oncologists with the available evidence concerning COVID-19 in cancer patients in order to better guide management decisions.
This Editorial presents a Lebanese institution’s experience managing cancer patients during the pandemic, and their attempts to follow the guidelines of the Lebanese Society of Medical Oncology.
This White Paper from the Colorectal Cancer Alliance and the Georgetown University Lombardi Comprehensive Cancer Center (both DC, USA) presents practical guidelines and recommendations for the management of colorectal cancer during the COVID-19 pandemic.
This Editorial sees the society share guidelines and recommendations for cancer care during the current pandemic. The article is particularly relevant for healthcare practitioners in low-resource settings.
This Editorial assesses the safety of immune checkpoint inhibitor administration in cancer patients during the current pandemic.
Time to presentation is a key determinant of outcome in melanoma. This Editorial discusses at-home examination for melanoma, and highlights how during times of restricted access to healthcare – such as during the COVID-19 pandemic – those at risk would benefit from the ability to self screen.
This commentary discusses the potential impact of COVID-19 on therapeutic decision-making for cancer patients.
If you would like to keep up to date with our content on coronavirus, you can sign up for our site here, where you can subscribe to our newsletters for free!
Chih-Jung Kuo et al. from National Taiwan University (Taipei, Taiwan) used SARS biology to construct vectors and present a protease for recombinant protein production.
Leonie-Sophie Hecht and colleagues from altona Diagnostics GmbH (Hamburg, Germany) evaluate a confirmatory RT-PCR kit targeting the MERS-CoV N gene.
In this review from Entedar A J Alsaadi (Thiqar University, Iraq) and Ian M Jones (University of Reading, UK), the role of coronavirus-encoded proteins with membrane-binding properties are discussed, with a focus on their role in replication.
Here, To Sing Fung and Ding Xiang Liu from South China Agricultural University (Guangdong, China) summarize post-translational modifications of coronavirus proteins, and their impact on replication and pathogenesis.
STAT3 has been shown to affect viral infection and pathogenicity, including of SARS-CoV. This review summarizes that role and the molecular mechanisms involved.
Here, Brigitte A Wevers and Lia van der Hoek (University of Amsterdam, The Netherlands) discuss the involvement of proteases of the renin-angiotensin system in coronavirus pathogenesis.
In this perspective, Jennifer R Tisoncik and colleagues (University of Washington, USA) discuss the role of systems biology in understanding host—virus interactions and developing drugs and vaccines.
This review examines the role of interferons during SARS-CoV infection, and the implications for treatment.
Dale L Barnard (Utah State University, USA) reviews the book of the same name, which presents a comprehensive review of the coronavirus virology field.
Despite intensive research between the emergence of SARS in 2003 and the drafting of this review in 2011, it remained untreatable. This review explored the development and promise of chemotherapeutic compounds.
This 2013 editorial examines the possible treatment strategies for MERS-CoV.
Jonathan P Wong et al. from the Suffield Research Centre (Alberta, Canada) discuss experimental strategies for treating hypercytokinema caused by a variety of viruses, and their potential application to the clinic.
Timothy P Sheahan and Ralph S Baric (University of North Carolina at Chapel Hill, NC, USA) discuss their experience in developing therapeutics against SARS-, MERS- and zoonotic CoV in an ever-changing regulatory environment.
This review focuses on host resilience mechanisms that could be exploited against SARS- or MERS-CoV, along with other viruses causing respiratory problems.
This article comments on the work of Coughlin et al. (Virology 394, 39—46 ), which discussed passive immunotherapy based on neutralizing human monoclonal antibodies, and its potential for treatment of SARS.
This editorial discussed the challenges facing clinical development of a SARS vaccine.
This 2015 editorial summarizes the progress in therapeutic monoclonal antibodies and animal models for MERS.
In this 2011 report, Burtram C Fielding (University of the Western Cape, South Africa) examined HCoV-NL63, with a focus on lower respiratory tract symptoms.
This review summarizes current understanding of MERS-CoV – in terms of pathogenesis, prevention and control, and the development of vaccines and therapeutics.
Inoculation of the neurotopic JHM strain of mouse hepatitis virus, a member of the Coronaviridae family, in the CNS of susceptible mice results in encephalomyelitis. This review discussed the role of CXCR2 signalling in the resulting host response.
This 2015 perspective sees Michael Edelstein and David L Heymann (Center on Global Health Security, London, UK) propose an approach combining research, surveillance, control, preparedness and communication to prevent MERS-CoV spread.
Myths about the novel coronavirus, COVID-19, are spreading through the population faster than the disease itself, so what do you really need to know about the ongoing pandemic?
Drug repurposing – anti-malarials
Chloroquine is an antimalarial drug used in the treatment of Plasmodium vivax malaria. Three methods to quantify chloroquine and its metabolite in blood matrices were developed and validated in this research piece.
This research presents a synthesized scaffold that can act as a therapeutic template for further synthetic modifications toward the search for a new antimalarial agent.
This work presents the first pharmacogenetic report of an association between chloroquine/primaquine responses with OATP transporters.
Here, four hHDAC6 inhibitors showed submicromolar potency against both a chloroquine-sensitive and a chloroquine-resistant strain of Plasmodium falciparum with high selectivity indices, pointing to the relevance of exploring hHDAC6 inhibitors as potential new antiplasmodial agents.
This study investigates CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 genetic polymorphisms influence on chloroquine/primaquine treatment.
This article presents a validated method that has been successfully used in a PK study in miniature pigs, and paves the way for future development.
This Editorial evaluates the problem of artemisinin resistance and the risk to success of the malaria control and elimination program.
This article reviews the discovery of dual-function antimalarials that are proposed to target both hemozoin formation and the chloroquine resistance transporter, PfCRT and discusses them in relation to the mechanism of action of 4-aminoquinolines, chloroquine resistance and resistance reversal.
The aim of this developed assay is to help determine drug use in these areas and also to be a complement to interviewing patients, which will increase reliability of surveys.
This review briefly summarizes the progress in understanding of the biochemistry of chloroquine resistance, and discusses where additional work is needed.
This review describes the transition from the proposed use of type I IFN as antiviral drugs in HIV infection, to the idea that blocking their activity or production may provide an immunologic benefit of much greater importance than their antiviral activity.
This review discusses the recommended treatment options for congenital malaria.
This article reviews and predicts the possible relevance, or lack of, of CYP2C8 polymorphisms in the present and future efficacy of amodiaquine. Chloroquine and dapsone, both substrates of CYP2C8, are also discussed in the same context.
This article reviews the molecular basis of the action of, and resistance to, different antimalarials and examines the prospects for the next generation of drugs to combat this potentially lethal human pathogen.
For updates on the coronavirus outbreak, as well as the latest recommendations and tips for reducing the spread of the disease, check the WHO coronavirus page.
For definitions and basic info on COVID-19, read Coronavirus Disease 2019 (COVID-19) – Signs, Symptoms and Diagnosis.
If you want to keep up to date with the latest stats, vaccines and therapeutics concerning coronavirus please visit our sister site ID Hub’s In focus on coronavirus.